Skip to main content
Log in

Body mass index is a prognostic factor in adult patients with acute myeloid leukemia

International Journal of Hematology Aims and scope Submit manuscript

Abstract

Body mass index (BMI), which represents the proportion of weight to height, is a controversial prognostic factor for acute myeloid leukemia (AML). We evaluated prognostic value of BMI in Japanese AML. The study included 369 adult patients with newly diagnosed AML who were administered either daunorubicin or idarubicin with cytarabine as induction chemotherapy. The patients were categorized into two groups according to their BMI: the NW group (BMI < 25.0 kg/m2; normal and underweight) and OW group (BMI ≥ 25.0 kg/m2; overweight and obese). We analyzed treatment efficacy and toxicity of induction chemotherapy, and survival outcomes in each group. Patients in the OW group showed a better complete remission rate than the NW group (86.1 versus 76.5%, P = 0.045), no early death (0.0 versus 4.1%, P = 0.042), and better overall survival (OS) at 3 years (62.2 versus 50.1%, P = 0.012). Multivariate analysis showed BMI is an independent prognostic factor for OS (hazard ratio 0.62, 95% confidence interval 0.42–0.92, P = 0.017). These results indicate the prognostic value of BMI in adult AML patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Yoshiike N, Miyoshi M. Epidemiological aspects of overweight and obesity in Japan–international comparisons. Nihon Rinsho. 2013;12(71):207–16.

    Google Scholar 

  2. WHO Technical Report Series 854. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organization, Geneva 1995.

  3. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.

    Article  PubMed  Google Scholar 

  4. Lewis CE, McTigue KM, Burke LE, Poirier P, Eckel RH, Howard BV, et al. Mortality, Health Outcomes, and Body Mass Index in the Overweight Range. Circulation. 2009;119:3263–71.

    Article  PubMed  Google Scholar 

  5. De Pergola G, Silvestris F. Obesity as a Major Risk Factor for Cancer. J Obes. 2013;2013:291546.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA. 2005;293:203–11.

    Article  CAS  PubMed  Google Scholar 

  7. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322–33.

    CAS  PubMed  Google Scholar 

  8. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649–55.

    Article  CAS  PubMed  Google Scholar 

  9. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2011;24(117):2358–65.

    Article  Google Scholar 

  10. Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011;24(117):2366–72.

    Article  Google Scholar 

  11. Yamazaki E, Kanamori H, Itabashi M, Ogusa E, Numata A, Yamamoto W, et al. Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia. Leukemia Lymphoma. 2017;58(1):104–9.

    Article  CAS  PubMed  Google Scholar 

  12. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2004;21:4642–9.

    Article  Google Scholar 

  13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J. 1958;53:457–81.

    Article  Google Scholar 

  14. Cox DR. Regression models and life tables. J R Stat Soc Series B Stat Methodol. 1972;34:187–220.

    Google Scholar 

  15. Kanda Y. Investigation of the freely-available easy-to-use software “EZR” (Easy R) for medical statistics. Bone Marrow Transplant. 2012;2013:48,452–48,458. doi:10.1038/bmt.2012.244 (Advance online publication 3).

  16. Nazare JA, Smith J, Borel AL, Aschner P, Barter P, Van Gaal L, et al. Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA study). Am J Cardiol. 2015;115:307–15.

    Article  PubMed  Google Scholar 

  17. Kodama S, Horikawa C, Fujihara K, Yoshizawa S, Yachi Y, Tanaka S, et al. Quantitative relationship between body weight gain in adulthood and incident type 2 diabetes: a meta-analysis. Obes Rev. 2014;15:202–14.

    Article  CAS  PubMed  Google Scholar 

  18. Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA. 2005;293:203–11.

    Article  CAS  PubMed  Google Scholar 

  19. Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S. Criteria and classification of obesity in Japan and Asia-Oceania. Asia Pac J Clin Nutr. 2002;11(8):732–7.

    Article  Google Scholar 

  20. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol. 1988;6:1321–7.

    Article  CAS  PubMed  Google Scholar 

  21. Krogh-Madsen M, Bender B, Jensen MK, Nielsen OJ, Friberg LE, Honoré PH. Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia. Cancer Chemother Pharmacol. 2012;69:155–1163.

    Article  Google Scholar 

  22. Murry DJ, Riva L, Poplack DG. Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl. 1998;11:48–51.

    Article  CAS  PubMed  Google Scholar 

  23. Boullata JI. Drug disposition in obesity and protein-energy malnutrition. Proc Nutr Soc. 2010;69:543–50.

    Article  CAS  PubMed  Google Scholar 

  24. Wilkinson GR. Drug Metabolism and Variability among Patients in Drug Response. N Engl J Med. 2005;352:2211–21.

    Article  CAS  PubMed  Google Scholar 

  25. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–41.

    Article  CAS  PubMed  Google Scholar 

  26. Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, et al. Benefits of high dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016;24(127):1551–8.

    Article  Google Scholar 

  27. Medeiros BC, Othus M, Estey EH, Fang M, Appelbaum FR. Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica. 2012;97:1401–4.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Fuji S, Takano K, Mori T, Eto T, Suzuki R, Fukuda T, et al. Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. Biol Blood Marrow Transplant. 2014;49(12):1505–12.

    Article  CAS  Google Scholar 

  29. Le Blanc K, Ringden O, Remberger M. A low body mass index is correlated with poor survival after allogeneic stem cell transplantation. Haematologica. 2003;88:1044–52.

    PubMed  Google Scholar 

  30. Deeg HJ, Seidel K, Bruemmer B, Pepe MS, Appelbaum FR. Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transplant. 1995;15:461–8.

    CAS  PubMed  Google Scholar 

  31. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, et al. Appropriate chemotherapy dosing for obese adults patients with cancer: American society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30:1553–61.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was conducted by the Yokohama Cooperative Study Group for Hematology (YACHT) and any of the seven hospitals collaborate to form the Yokohama City University Hematology Group.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Etsuko Yamazaki.

Ethics declarations

Conflict of interest

Hiroyuki Fujita has the following financial relationship to disclose: Honoraria (manuscript fee) from Chugai Pharmaceutical CO., LTD.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PPTX 171 kb)

Supplementary material 2 (XLSX 9 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ando, T., Yamazaki, E., Ogusa, E. et al. Body mass index is a prognostic factor in adult patients with acute myeloid leukemia. Int J Hematol 105, 623–630 (2017). https://doi.org/10.1007/s12185-017-2183-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-017-2183-7

Keywords

Navigation